Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Suzanne Demko"'
Autor:
Mohamed S. Abdelbaki, Mariko Dawn DeWire Schottmiller, Timothy P. Cripe, Richard C. Curry, Charles A. Cruze, Leah Her, Suzanne Demko, Denise Casey, Bhuvana Setty
Publikováno v:
Heliyon, Vol 8, Iss 12, Pp e12450- (2022)
Background: BXQ-350 is a novel anti-neoplastic agent composed of saposin C (SapC) and phospholipid dioleoylphosphatidyl-serine sodium (DOPS) that selectively binds tumor cell phosphatidylserine (PS), inducing apoptosis. BXQ-350 has demonstrated precl
Externí odkaz:
https://doaj.org/article/8548165f27c04ab687a6cbd2a4192cf7
Autor:
Arup Kumar Sinha, Olen Stephens, Marc R. Theoret, Mei Ou, R. Pazdur, Gregory H. Reaman, Katherine Windsor, Yuching Yang, Suzanne Demko, Denise Casey, Kirsten B. Goldberg, Harpreet Singh, Abhilasha Nair, Jianghong Fan, Yuan Li Shen, Ruby Leong, Whitney S. Helms, M. Anwar Goheer, Byeongtaek Oh, Jiang Liu, Vishal Bhatnagar, Sachia Khasar, Selena R. Daniels, Stacy Shifflett Shord, Sharon Sickafuse, Lili Pan, Yuan Xu, Pallavi Mishra-Kalyani
Publikováno v:
Clinical Cancer Research. 27:4142-4146
On April 10, 2020, the FDA approved selumetinib (KOSELUGO, AstraZeneca) for the treatment of pediatric patients 2 years of age and older with neurofibromatosis type 1 who have symptomatic, inoperable plexiform neurofibromas. Approval was based on dem
Autor:
Patricia Keegan, Hong Zhao, Denise Casey, Alexander H. Putman, Richard Pazdur, Stacy S. Shord, Huanyu Chen, Whitney S. Helms, Kun He, Suzanne Demko
Publikováno v:
Clinical Cancer Research. 23:2377-2381
On July 24, 2015, the FDA approved sonidegib (ODOMZO; Novartis) for the treatment of patients with locally advanced basal cell carcinoma (laBCC) not amenable to curative surgery or radiotherapy. The approval was based on data from one randomized, dou
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 23(19)
Race and ethnicity are important considerations during drug development, with differential effects in drug exposure, efficacy, and safety across racial groups observed for some drugs. Gyawali and Ando ([1][1]) suggest that the recommended dose of 200
Autor:
Xiaoping Jiang, Martin H. Cohen, Joseph E. Gootenberg, Kun He, Patricia Keegan, Richard Pazdur, Thomas M. Herndon, Suzanne Demko
Publikováno v:
The Oncologist. 17:1323-1328
Learning Objectives After completing this course, the reader will be able to: Describe the setting in which the use of peginterferon-alfa-2b is appropriate for melanoma patients.Define the expectations with regard to survival and side effect profile
Autor:
Stacy Shifflett Shord, Liang Zhao, Denise Casey, Nam Atiqur Rahman, Ping Zhao, Hong Zhao, Brian Booth, Patricia Keegan, Suzanne Demko
Publikováno v:
Journal of Clinical Oncology. 34:e14121-e14121
e14121Background: On July 24, 2015, FDA approved Odomzo (sonidegib) for the treatment of patients with locally advanced basal cell carcinoma. At the recommended dose of 200mg once daily, 68% of pat...
Publikováno v:
The oncologist. 13(2)
Learning Objectives After completing this course, the reader will be able to: Discuss the results of the CAM 307 randomized trial of alemtuzumab in patients with B-cell chronic lymphocytic leukemia.Describe the pretreatment and prophylactic medicatio
Autor:
Suzanne Demko, Brian Booth, Ruthann Marie Giusti, Jun Yang, Nitin Mehrotra, Nam Atiqur Rahman, Hong Zhao, Patricia Keegan
Publikováno v:
Journal of Clinical Oncology. 31:2510-2510
2510 Background: On November 29 2012, the U. S. FDA approved cabozantinib (COMETRIQ) for the treatment of patients with progressive, metastatic medullary thyroid cancer (MTC). Drug-related toxicity was common at a dose of 140 mg once daily across Pha
Autor:
Bradford, Diana, Demko, Suzanne, Jin, Susan, Mishra‐Kalyani, Pallavi, Beckles, Aaliyah R., Goldberg, Kirsten B., Lemery, Steven, Ward, Ashley, Keegan, Patricia, Pazdur, Richard
Publikováno v:
Oncologist; Jul2020, Vol. 25 Issue 7, pe1077-e1082, 6p, 5 Charts
Publikováno v:
Oncologist; Feb2008, Vol. 13 Issue 2, p167-174, 9p, 5 Charts, 1 Graph